Bone morphogenetic protein-SMAD1 signaling pathway (BMP-SMAD1 pathway)

The bone morphogenetic protein-SMAD1 signaling pathway is a well-characterized intracellular signaling cascade initiated by the binding of bone morphogenetic protein (BMP) ligands to type I and type II serine/threonine kinase BMP receptors.[2][3][5][7] Ligand binding leads to receptor activation and phosphorylation of receptor-regulated SMADs—specifically SMAD1 (along with SMAD5 and SMAD8).[2][4][5] Phosphorylated SMAD1 associates with SMAD4 (or, in some cell types, acts independently of SMAD4) and translocates to the nucleus, where it regulates gene transcription associated with development, organogenesis, and tissue homeostasis.[1][2][3] This pathway is critical in numerous biological processes such as chondrogenesis (cartilage development), bone formation, and tooth morphogenesis, and disruption leads to developmental disorders.[2][4][5][7] SMAD1 itself is classified as a transcription factor activated by upstream kinase signaling (BMP receptors). The “BMP-SMAD1 pathway” is not a single molecule or canonical drug target, but a signaling axis with the key effector being SMAD1 and its transcriptional regulatory activity.

Other names

BMP-SMAD1 axisBMP canonical signaling pathway (when referring to the Smad1 branch)BMP/Smad1 pathway

Small molecule inhibitors (e.g., dorsomorphin) inhibit BMP receptor kinases, blocking phosphorylation of SMAD1/5/8, and downstream signaling[2] - Ligand traps bind to and neutralize BMP ligands (not specific to SMAD1 but affect the pathway)